S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia

Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004)
Neuropsychopharmacology 29(5): 1004-1011.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ; ;
Abstract / Notes
S100B, a calcium-binding protein produced by astroglial cells, mediates paracrine and autocrine effects on neurons and glial cells. It regulates the balance between proliferation and differentiation in neurons and glial cells by affecting protective and apoptotic mechanisms. Post-mortem studies have demonstrated a deficit in synapses and dendrites in brains of schizophrenics. Recent studies have shown increased S100B levels in medicated acutely psychotic schizophrenic patients as well as unmedicated or drug naive schizophrenics. One study reported a positive correlation between negative symptoms and S100B. S100B serum levels (quantitative immunoassay) and psychopathology (Positive and Negative Syndrome Scale, PANSS) were examined upon study admission and after 12 and 24 weeks of standardized treatment in 98 chronic schizophrenic patients with primarily negative symptoms. Compared to age- and sex-matched healthy controls, the schizophrenic patients showed significantly increased S100B concentrations upon admission and after 12 and 24 weeks of treatment. High PANSS negative scores were correlated with high S100B levels. Regression analysis comparing psychopathology subscales and S100B identified negative symptomatology as the predicting factor for S100B. S100B is not just elevated during acute stages of disease since it remains elevated for at least 6 months following an acute exacerbation. With regard to psychopathology, negative symptomatology appears to be the predicting factor for the absolute S100B concentration. This might indicate that S100B in schizophrenic patients either promotes apoptotic mechanisms by itself or is released from astrocytes as part of an attempt to repair a degenerative or destructive process.
Publishing Year
ISSN
PUB-ID

Cite this

Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology. 2004;29(5):1004-1011.
Rothermundt, M., Ponath, G., Glaser, T., Hetzel, G., & Arolt, V. (2004). S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology, 29(5), 1004-1011. doi:10.1038/sj.npp.1300403
Rothermundt, M., Ponath, G., Glaser, T., Hetzel, G., and Arolt, V. (2004). S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29, 1004-1011.
Rothermundt, M., et al., 2004. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology, 29(5), p 1004-1011.
M. Rothermundt, et al., “S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia”, Neuropsychopharmacology, vol. 29, 2004, pp. 1004-1011.
Rothermundt, M., Ponath, G., Glaser, T., Hetzel, G., Arolt, V.: S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology. 29, 1004-1011 (2004).
Rothermundt, M, Ponath, G, Glaser, Thorsten, Hetzel, G, and Arolt, V. “S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia”. Neuropsychopharmacology 29.5 (2004): 1004-1011.
This data publication is cited in the following publications:
This publication cites the following data publications:

50 Citations in Europe PMC

Data provided by Europe PubMed Central.

Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia.
Zhai J, Zhang Q, Cheng L, Chen M, Wang K, Liu Y, Deng X, Chen X, Shen Q, Xu Z, Ji F, Liu C, Dong Q, Chen C, Li J., Behav Brain Res 217(2), 2011
PMID: 21070816
Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder.
Dagdan E, Morris DW, Campbell M, Hill M, Rothermundt M, Kästner F, Hohoff C, von Eiff C, Krakowitzky P, Gill M, McKeon P, Roche S., Am J Med Genet B Neuropsychiatr Genet 156B(6), 2011
PMID: 21714070
Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
Zhang XY, Xiu MH, Chen DC, Zhu FY, Wu GY, Haile CN, Lu L, Kosten TA, Kosten TR., J Psychiatr Res 44(7), 2010
PMID: 19932492
Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals.
Hohoff C, Ponath G, Freitag CM, Kästner F, Krakowitzky P, Domschke K, Koelkebeck K, Kipp F, von Eiff C, Deckert J, Rothermundt M., Am J Med Genet B Neuropsychiatr Genet 153B(1), 2010
PMID: 19330775
Haloperidol and clozapine decrease S100B release from glial cells.
Steiner J, Schroeter ML, Schiltz K, Bernstein HG, Müller UJ, Richter-Landsberg C, Müller WE, Walter M, Gos T, Bogerts B, Keilhoff G., Neuroscience 167(4), 2010
PMID: 20226844
Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis.
Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE., Psychiatry Res 167(1-2), 2009
PMID: 19375171
Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics.
Qi LY, Xiu MH, Chen DC, Wang F, Kosten TA, Kosten TR, Zhang XY., Neurosci Lett 462(2), 2009
PMID: 19539717
Breaching the blood-brain barrier as a gate to psychiatric disorder.
Shalev H, Serlin Y, Friedman A., Cardiovasc Psychiatry Neurol 2009(), 2009
PMID: 19936105
S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study.
Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H, Brisch R, Gos T, Mawrin C, Myint AM, Bogerts B., J Psychiatr Res 42(10), 2008
PMID: 18001771
Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia.
Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, Kipp F, Abel S, Siegmund A, Suslow T, von Eiff C, Arolt V, Rothermundt M., Prog Neuropsychopharmacol Biol Psychiatry 32(8), 2008
PMID: 18718498
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.
Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmächer T, Maier W, Sirén AL, Klosterkötter J, Falkai P, Rüther E, Aldenhoff JB, Krampe H., Mol Psychiatry 12(2), 2007
PMID: 17033631
Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol.
Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, Suslow T, Peters M, Kaestner F, Heindel W, Arolt V, Pfleiderer B., Prog Neuropsychopharmacol Biol Psychiatry 31(2), 2007
PMID: 17081670
Increased serum S100B protein in chronic schizophrenic patients in Korea.
Ryoun Kim H, Kyung Lee M, Park DB., Clin Chem Lab Med 45(11), 2007
PMID: 17970711
Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites.
Nilsson-Todd LK, Nordin C, Jönsson EG, Skogh E, Erhardt S., Acta Neuropsychiatr 19(1), 2007
PMID: 26952797
Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment.
Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E., Prog Neuropsychopharmacol Biol Psychiatry 31(6), 2007
PMID: 17459548
Schizophrenia-associated neural growth factors in peripheral blood. A review.
van Beveren NJ, van der Spelt JJ, de Haan L, Fekkes D., Eur Neuropsychopharmacol 16(7), 2006
PMID: 16545550
S100B and NSE serum concentrations in Machado Joseph disease.
Tort AB, Portela LV, Rockenbach IC, Monte TL, Pereira ML, Souza DO, Rieder CR, Jardim LB., Clin Chim Acta 351(1-2), 2005
PMID: 15563883
Is there an immunologic basis for schizophrenia?
Leonard BE., Expert Rev Clin Immunol 1(1), 2005
PMID: 20477658
Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.
Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, Falkai P., Schizophr Res 80(2-3), 2005
PMID: 15964742
Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.
Rothermundt M, Falkai P, Ponath G, Abel S, Bürkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V., Mol Psychiatry 9(10), 2004
PMID: 15241436

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 14997170
PubMed | Europe PMC

Search this title in

Google Scholar